Association of SLC14A1C/T Polymorphisms in Patients with Bladder Cancer in Comparison with Healthy Controls

Saziya Bidi; R.B Nerli; Shadab Rangrez; Shridhar C. Ghagane

doi:10.1055/s-0045-1805081

South Asian Journal of Cancer, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · South Asian J Cancer 2025; 14(04): 810-814
DOI: 10.1055/s-0045-1805081

Original Article

Genito Urinary Section

Association of SLC14A1C/T Polymorphisms in Patients with Bladder Cancer in Comparison with Healthy Controls

Autor*innen

Saziya Bidi

¹Urinary Biomarkers Research Centre, KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Nehru Nagar, Belagavi, Karnataka, India

²Department of Urology, JN Medical College, KLE Academy of Higher Education & Research (Deemed-to-be-University), JNMC Campus, Belagavi, Karnataka, India
R.B Nerli

¹Urinary Biomarkers Research Centre, KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Nehru Nagar, Belagavi, Karnataka, India

²Department of Urology, JN Medical College, KLE Academy of Higher Education & Research (Deemed-to-be-University), JNMC Campus, Belagavi, Karnataka, India
Shadab Rangrez

³Department of Biochemistry, JGMM Medical College, Hubballi, Karnataka, India
Shridhar C. Ghagane

¹Urinary Biomarkers Research Centre, KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Nehru Nagar, Belagavi, Karnataka, India

⁴KAHER's Dr. Prabhakar Kore Basic Science Research Center, KLE Academy of Higher Education & Research, JNMC Campus, Belagavi, Karnataka, India

Abstract

Background

Transitional cell carcinoma of the urinary bladder is one of the most common malignancies affecting the urinary tract. Genomic instability is one of the most important common features of urothelial cancers of the bladder. Gene polymorphisms of the SLC14A1 gene are known to be related to carcinogenesis of the bladder in humans. Similarly, the use of tobacco products including chewing and smoking is an established risk factor for bladder cancer in both men and women. The primary aim of the study was to assess the relationship between bladder cancer and polymorphisms of the SLC14A1 gene (rs17674580) in our patients with image and histologically confirmed bladder cancer and secondarily to assess if use of tobacco products in these patients further accentuated the risk of bladder cancer.

Patients and Methods

All patients aged ≥18 years with images (ultrasonography/computed tomography) and histologically confirmed bladder cancer formed the study group. Age- and gender-matched individuals aged ≥18 years, genetically unrelated, formed the controls. A 2-mL blood sample was collected from patients as well as controls, for genotyping of SLC14A1C/T gene polymorphisms. Demographic data were obtained from all the participants, and individuals who smoked once a day for more than 5 years were defined as smokers. Similarly, patients who chewed tobacco for more than 5 years were defined as tobacco users.

Results

During the study period, 107 patients (84 males and 23 females) with image and histologically confirmed bladder cancer formed the study group. The mean age of the patients with bladder cancer was 58.47 ± 14.5 years and that of the controls was 60.01 ± 12.5 years. Among patients with bladder cancer, 28 (26.2%) showed no polymorphisms (rs17674580) of the SLC14A1 gene, whereas 79 (73.8%) patients showed polymorphisms. Heterozygous variations (CT) were noted in 46 (42.9%) patients, whereas homozygous variations were noted in 33 (30.9%) patients with the odds ratio being 2.772 (1.459–3.247) and 3.349 (1.610–6.922), respectively. The use of tobacco (smoking/chewing) was also found to modulate risks of bladder cancer in SLC14A1 variants.

Conclusion

Gene polymorphisms of SLC14A1C/T are associated with a high risk of bladder cancer in our group of patients in South India. Moreover, the use of tobacco, be it smoking or chewing, further increases the risk of bladder cancer in these patients.

Keywords

gene polymorphisms - transitional cell carcinoma - tobacco (smoking/chewing) - histopathology - south India

Volltext

Referenzen

References
1 Rosenberg JE, Hoffman-Censits J, Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387 (10031): 1909-1920
2 Audenet F, Isharwal S, Cha EK. et al. Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma. Clin Cancer Res 2019; 25 (03) 967-976
3 Nerli RB, Ghagane SC, Shankar K. et al. Low-grade, multiple, Ta non-muscle-invasive bladder tumors: tumor recurrence and worsening progression. Indian J Surg Oncol 2018; 9 (02) 157-161
4 Nerli RB, Ghagane SC, Rangrez S, Chandra S, Thakur ML, Gomella L. Detection of bladder cancer using voided urine sample and by targeting genomic VPAC receptors. Indian J Urol 2021; 37 (04) 345-349
5 Kallioniemi A, Kallioniemi OP, Citro G. et al. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer 1995; 12 (03) 213-219
6 Puranik SI, Ghagane SC, Nerli RB, Hiremath MB. Incidence of bladder cancer at a tertiary care centre in north Karnataka. Middle East J Cancer 2022; 13 (02) 363-371
7 Shayakul C, Clémençon B, Hediger MA. The urea transporter family (SLC14): physiological, pathological and structural aspects. Mol Aspects Med 2013; 34 (2–3): 313-322
8 Rafnar T, Vermeulen SH, Sulem P. et al. European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet 2011; 20 (21) 4268-4281
9 Garcia-Closas M, Ye Y, Rothman N. et al. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet 2011; 20 (21) 4282-4289
10 Chan TC, Wu WJ, Li WM, Shiao MS, Shiue YL, Li CF. SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma. Theranostics 2020; 10 (25) 11775-11793
11 IARC. Tobacco Smoke and Involuntary Smoking. Lyon, France: IARC; 2004
12 Silverman DT, Devesa SS, Moore LE, Rothman N. Bladder cancer. In: Schottenfeld D, Fraumeni Jr JF. eds Cancer Epidemiology and Prevention. 3rd ed. New York, NY: Oxford University Press; 2006: 1101-1127
13 Hemelt M, Yamamoto H, Cheng KK, Zeegers MP. The effect of smoking on the male excess of bladder cancer: a meta-analysis and geographical analyses. Int J Cancer 2009; 124 (02) 412-419
14 Biggerstaff J. The relationship between the risk of smoking-related disease, inflammatory response and single-nucleotide polymorphisms. Microreviews Cell Molecular Biology 2019; 5 (01) 1-5
15 de Maturana EL, Rava M, Anumudu C, Sáez O, Alonso D, Malats N. Bladder cancer genetic susceptibility. A systematic review. Bladder Cancer 2018; 4 (02) 215-226
16 Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000; 89 (03) 630-639
17 Shadab R, Nerli RB, Bidi SR, Ghagane SC. Risk factors for bladder cancer: results of a survey of hospital patients. J Cancer Allied Spec 2023; 9 (01) 485
18 van Osch FH, Jochems SH, van Schooten FJ, Bryan RT, Zeegers MP. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol 2016; 45 (03) 857-870
19 Kamat AM, Hahn NM, Efstathiou JA. et al. Bladder cancer. Lancet 2016; 388 (10061): 2796-2810
20 Kwan ML, Haque R, Young-Wolff KC. et al. Smoking behaviors and prognosis in patients with non-muscle-invasive bladder cancer in the be-well study. JAMA Netw Open 2022; 5 (11) e2244430